AviaraDx, Inc. is a molecular cancer profiling company that is focused on developing and commercializing molecular diagnostic technologies with proven clinical utility. The Company leverages its technological leadership position in the analysis of cancer biopsies and proprietary bioinformatic methodologies to discover and validate novel diagnostic, prognostic and predictive biomarkers for better cancer treatment. Diagnostic laboratories in the US and Europe have licensed the Company’s molecular cancer identification (MCID) and breast cancer profiling (BCP) technologies to develop and commercialize certain laboratory tests.